Alexion Pharmaceuticals, Inc. (ALXN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Alexion Pharmaceuticals, Inc. (ALXN)

ALXN 182.50

0.0%

Jul 28 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Miljenko Zuanic who wrote (262)	2/21/2003 10:54:28 PM
From: keokalani'nui	of 824

>>time to enrollment completion is moved bit forward<< I don't think so. But only official company announcement will do. >>few other agents are also in similar PIII trials and it may effect enrollment and candidate visibility<< Recruiting patients not an issue, based on my small sample size. Anyway, since cariporide failure, is any other PIII cardio candidate seriously reaching for mortality benefit? Truth is, going to have a 3000 patient CABG PIII trial with a novel anti-inflammatory completed in about a year. Was in LA this last week. Weather was so fine!!!

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next